FR2385400A1 - Leucocytes stabilises - Google Patents

Leucocytes stabilises

Info

Publication number
FR2385400A1
FR2385400A1 FR7808865A FR7808865A FR2385400A1 FR 2385400 A1 FR2385400 A1 FR 2385400A1 FR 7808865 A FR7808865 A FR 7808865A FR 7808865 A FR7808865 A FR 7808865A FR 2385400 A1 FR2385400 A1 FR 2385400A1
Authority
FR
France
Prior art keywords
leukocytes
viability
maintains
medium
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR7808865A
Other languages
English (en)
Inventor
Hoda Antoun Guirgis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/858,129 external-priority patent/US4152208A/en
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of FR2385400A1 publication Critical patent/FR2385400A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne la préparation de leucocytes. Il s'agit d'un procédé pour maintenir la viabilité de leucocytes ; selon lequel a. on aspire le sang d'un patient ou d'un donneur directement dans un mélange d'un agent anti-coagulant et d'un milieu qui entretient la viabilité des leucocytes, b. on sépare les leucocytes par centrifugation vers une solution ayant une densité à peu près égale à celle des leucocytes que l'on sépare contenant un mélange d'un copolymère synthétique soluble dans l'eau de sucrose et d'épichlorhydrine d'une masse moléculaire moyenne de 400 000 +- 100 000 et du diatrizoate de sodium, c. on recueille les leucocytes et on les place dans des récipients contenant un milieu qui entretient la viabilité des leucocytes, ce milieu contenant des antibiotiques et une substance choisie parmi du sérum foetal de veau inactivé par la chaleur, des succédanés du type protéine équivalents au sérum foetal de veau inactivé par la chaleur et des dérivés de protéine équivalents au sérum foetal de veau inactivé par la chaleur. Ce procédé non seulement maintient la viabilité des leucocytes mais améliore leur récupération.
FR7808865A 1977-03-29 1978-03-28 Leucocytes stabilises Withdrawn FR2385400A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78259777A 1977-03-29 1977-03-29
US05/858,129 US4152208A (en) 1977-03-29 1977-12-06 Stabilized leucocytes

Publications (1)

Publication Number Publication Date
FR2385400A1 true FR2385400A1 (fr) 1978-10-27

Family

ID=27120014

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7808865A Withdrawn FR2385400A1 (fr) 1977-03-29 1978-03-28 Leucocytes stabilises

Country Status (6)

Country Link
JP (1) JPS53122283A (fr)
AT (2) ATA287878A (fr)
DE (1) DE2813548A1 (fr)
DK (1) DK136278A (fr)
FR (1) FR2385400A1 (fr)
GB (1) GB1581718A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0036168A2 (fr) * 1980-03-10 1981-09-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Procédé d'obtention de leucocytes et de thrombocytes intacts et viables à partir du sang

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CA1968 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0036168A2 (fr) * 1980-03-10 1981-09-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Procédé d'obtention de leucocytes et de thrombocytes intacts et viables à partir du sang
EP0036168A3 (en) * 1980-03-10 1982-05-12 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. A process for obtaining intact and viable leucocytes and thrombocytes from blood

Also Published As

Publication number Publication date
ATA287878A (de) 1981-02-15
DE2813548A1 (de) 1978-10-05
GB1581718A (en) 1980-12-17
JPS53122283A (en) 1978-10-25
AT364085B (de) 1981-09-25
DK136278A (da) 1978-09-30

Similar Documents

Publication Publication Date Title
O'Toole et al. Lymphocyte cytotoxicity in bladder cancer no requirement for thymus-derived effector cells?
Baldwin et al. Detection of circulating hepatoma D23 antigen and immune complexes in tumour bearer serum
Kohl et al. Defective natural killer cytotoxicity and polymorphonuclear leukocyte antibody-dependent cellular cytotoxicity in patients with LFA-1/OKM-1 deficiency.
NAJEAN et al. Survival of radiochromium-labeled platelets in thrombocytopenias
Pegels et al. Serological studies in patients on platelet‐and granulocyte‐substitution therapy
Evans et al. Chronic hemolytic anemia due to cold agglutinins: II. The role of C′ in red cell destruction
Stefanini et al. Platelets: VII. Shortened “Platelet Survival Time” and Development of Platelet Agglutinins Following Multiple Platelet Transfusions.
Melsom et al. The cytotoxic effect of mouse macrophages on syngeneic and allogeneic erythrocytes
Mellstedt et al. Monoclonal B‐Lymphocytes in Peripheral Blood of Patients with Plasma Cell Myeloma: Relation to Activity of the Disease
Vánkcy et al. Human tumor-lymphocyte interaction in vitro. VI. Specificity of primary and secondary autologous lymphocyte-mediated cytotoxicity
Gunson et al. An example of polyagglutinability due to the Tn antigen
CA1063019A (fr) Extrait du systeme hematopoietique
Bendinelli Haemolytic plaque formation by mouse peritoneal cells, and the effect on it of Friend virus infection
Minami et al. Dissociation of anti‐tumor immune responses in rats immunized with solubilized tumor‐associated antigens from a methylcholanthrene‐induced fibrosarcoma
Neumann et al. Immune interferon II. Different cellular site for the production of murine macrophage migration inhibitory factor and interferon
FR2385400A1 (fr) Leucocytes stabilises
Fassbinder et al. The role of formaldehyde in the formation of haemodialysis-associated anti-N-like antibodies
Le Deist et al. Graft vs graft reaction resulting in the elimination of maternal cells in a SCID patient with maternofetal GVHd after an HLA identical bone marrow transplantation.
Goust et al. Delayed hypersensitivity to muscle and thymus in myasthenia gravis and polymyositis
Evans et al. Consistently normal CD4+, CD8+ levels in haemophilic boys only treated with a virally safe factor VIII concentrate (BPL 8Y)
Netzel et al. TRANSPLANTATION OF SYNGENEIC BONE MARROW INCUBATED WITH LEUKOCYTE ANTIBODIES: II. CYTOTOXIC ACTIVITY OF ANTI-cALL GLOBULIN ON LEUKEMIC CELLS AND NORMAL HEMOPOIETIC PRECURSOR CELLS IN MAN
Pikovski et al. Peculiar gamma G in tumour cells and depletion of antibody forming organs in tumour bearing mice
Pross et al. Spontaneous human lymphocyte‐mediated cytotoxicity against tumor target cells. V. The role of serum‐derived heterologous membrane antigens
Hussein Babesia microti and Babesia hylomysci: spleen and phagocytosis in infected mice
Smith et al. Specificity of antileukemia sera prepared by immunization with leukemia cells admixed with normal antigen-blocking sera

Legal Events

Date Code Title Description
ST Notification of lapse